home / stock / hepa / hepa news

HEPA News and Press, Hepion Pharmaceuticals Inc. From 10/20/22

Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...
HEPA - Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
HEPA - Hepion Pharmaceuticals to Participate in the ThinkEquity Conference

EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

HEPA - Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

EDISON, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NAS...

HEPA - Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical's Rencofilstat to Treat Alcohol-Related Liver Disease

EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NAS...
HEPA - Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional Biomarkers - - F3 NASH Subjects will be Evaluated on Three Doses of Rencofilstat for a Four-month Period - EDISON, N.J...

HEPA - Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

EDISON, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NAS...

HEPA - Hepion Pharma rises as company begins NASH treatment trial

Hepion Pharma ( NASDAQ: HEPA ) is trading 4% higher after the company said it had screened the first subject in the nonalcoholic steatohepatitis ( NASH ), a fatty liver disease, clinical trial testing rencofilstat in 336 subjects dosed for 12 months. ...
HEPA - Hepion Pharmaceuticals Announces Initiation of Phase 2b 'ASCEND-NASH' Trial

- Hepion Screens First Subject in Biopsy-Confirmed F2/F3 NASH Study - - Subjects will be Evaluated on Three Doses of Rencofilstat for a One-year Period - EDISON, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmac...

HEPA - Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“...

HEPA - Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“...
Previous 10 Next 10